BIOHM Technologies

About BIOHM Technologies

BIOHM Technologies is a microbiome company that develops targeted products based on the interaction between bacteria and fungi in the gut. The company was co-founded in 2016 by Dr. Mahmoud Ghannoum, a leading microbiome researcher with over 40 years of experience, and his son, Afif Ghannoum, a biotechnology attorney. Dr. Ghannoum is the Director of the Center for Medical Mycology at Case Western Reserve University and was the first to identify the critical role of fungi in the gut, coining the term 'mycobiome'. His research revealed that bacteria and fungi can work together to create digestive plaque, known as biofilm, leading to imbalance.

This scientific basis led to the creation of BIOHM. Initially a direct-to-consumer brand called BIOHM Health, the company has shifted its focus to become BIOHM Technologies, a B2B solutions provider for the nutraceutical industry. The company's business model is centered on leveraging its extensive dataset of gut bacterial and fungal populations to create clinically studied ingredients and products. Revenue is generated through the sale of its proprietary ingredients to other brands and by offering private-label comprehensive microbiome gut testing kits. Their clients are primarily brands in the health and wellness space looking to incorporate scientifically validated microbiome solutions into their product lines.

The company’s flagship ingredient is Mycohsa™ (formerly BIOHM FX), a probiotic blend that has been clinically shown to break down digestive biofilms and support the balance of both bacteria and fungi. Beyond ingredient formulation, BIOHM Technologies also provides partners with services such as bioinformatics, product development, and clinical trial support, leveraging one of the largest microbiome datasets in the world. The company utilizes AI technology to enhance its targeted formulation process.